Open AccessRelationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
Author(s) -
Rey Jacques,
Poitiers Franck,
Paehler Tobias,
Brunet Aurélie,
DiCioccio A. Thomas,
Can Christopher P.,
Surks Howard K.,
Pinquier JeanLouis,
Hanotin Corinne,
Sasiela William J.
Publication year - 2016
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.116.003323
Subject(s) - alirocumab , ezetimibe , fenofibrate , medicine , pcsk9 , endocrinology , placebo , kexin , statin , lipoprotein , pharmacology , cholesterol , ldl receptor , alternative medicine , apolipoprotein a1 , pathology
Alirocumab undergoes target-mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid-lowering therapies are unclear. Every-4-weeks dosing of alirocumab may be appropriate for some patients in absence of background statin but is not yet approved.